ASH 2021 | High-dose methotrexate in the treatment of aggressive B-cell lymphoma
In this video, Katharine L. Lewis, BMBS, FRCPath, MRCPath, Sir Charles Gairdner Hospital, Nedlands, Australia, reports on findings from a multi-center retrospective analysis which aimed to evaluate the effectiveness of high-dose methotrexate in reducing the risk of central nervous system (CNS) relapse in patients with aggressive B-cell lymphoma. First, Dr Lewis explains the background information for this study, including CNS relapse and how patient risk for this complication is calculated using the CNS international prognostic index (CNS-IPI). Following this, Dr Lewis explains the methodology and results obtained from this retrospective analysis, and the benefits of adding this data to the current literature in the field. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
Disclosures
AstraZeneca – consultancy and honoraria Janssen – honoraria and conference attendance Novartis – conference attendance Roche – consultancy and honoraria
